---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-002227"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:49:10.327010+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M

## Summary
- Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.
- Operating expenses down 23% YoY; post-year-end raised $2.3M equity and $1.8M non-dilutive funding.
- Sold ~120,000 Nu.Q Vet Cancer Tests; available in 20+ countries; active commercial discussions for human diagnostics.
- Goal to be cash neutral in 2025 via licensing receipts and revenue.
- Board strengthened with new Chair Timothy Still and Director Dr. Ethel Rubin.

## SEC filing metadata
- accession: 0001477932-25-002227
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793225002227/0001477932-25-002227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793225002227/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-002227
- JSON: https://secwatch.observer/filing/0001477932-25-002227.json
- Plain text: https://secwatch.observer/filing/0001477932-25-002227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.